America’s coronavirus: confirmed cases do not show ‘total burden’ of epidemic, study says

Researchers at the University of California Berkeley School of Public Health have suggested that the case in the US “cannot capture the total burden of the epidemic because testing is limited to individuals with moderate to severe symptoms mainly because of limited test availability.”

Jade Benjamin-Chung, one of the co-authors in the study and professor of epidemiology and biology at Berkeley Public, said, “We know that in the US, people who tested earlier on the epidemic had moderate to severe symptoms. ” Health. “And we know that since then, we have a large number of asymptomatic people who are affecting the total number of infections, but may not be involved in the confirmed case.”

The findings support previous statements by the Centers for Disease Control and Prevention which indicate that the number of cases in the country is much higher than considered. In June, CDC director Drs. Robert Redfield stated that the probability of trial missed in 90% or so of cases.

The vaccine will be effective or ‘it won’t go together,’ says the surgeon general

Dr. Francis Collins, director of the National Institutes of Health and Drs. Jerome Adams, US Surgeon General, pledged at a Senate hearing on Wednesday that he would receive the Kovid-19 vaccine if considered safe.

“As soon as he is effective, I think I’m ready to roll up my sleeves when he gets the vaccine in public view,” Collins said.

Both questioned the senators during the Senate Health Committee hearing on vaccines. Adams and Collins assured senators and the American public that the vaccine process was being led by science, not partisan politics.

Trump accepts this to hide the real threat of coronovirus in the new Woodward book;

“I want the American people to hear me say: There will be no shortcut. This vaccine will be safe. It will be effective. Or it will not be carried along,” Adams said. “And when a vaccine is approved or authorized by the FDA, I and my family will be in the queue to receive it.”

The comments come as the US continues to witness widespread Kovid-19 transitions, especially in areas where colleges have reopened. According to Johns Hopkins University, over the past seven days, the US has averaged over 36,000 daily new coronovirus cases.

More tests are needed, the report said

A new report states that the US should perform well over 200 million Kovid-19 tests next month to have any chance of controlling the epidemic.

That number is far away According to the report released on Wednesday by the Rockefeller Foundation and the Duke-Margolis Center for Health Policy, beyond the country’s current capacity.

The report states, “The US will require a much larger number of Kovid-19 tests of all types well into 2021, while the outbreak occurs with a particular need for more screening tests while returning to normal activity, Which is a very fast turnaround time. “ Reads.

Public health experts around the country have said for months that testing would play an important role in helping to reel in an epidemic. Having enough people tested – and getting their results back quickly – will assist contact trailers in tracking Americans exposed to the virus and help control outbreaks.

Latest on coronavirus epidemic

The report states that fewer than 30 million trials in the country are currently reported monthly. As the virus spread unabated in American communities over the summer, some officials said that contact tracing was almost impossible with lack of testing capability and uncontrolled proliferation.

White House Coronavirus Task Force test head Admit Brett Girir has said that repeatedly the US cannot test the way out of the epidemic.

Echoing the claims of other officials, reports from the team of experts say more testing is important.

The team wrote, “At the current infection rate, a basic screening strategy would require approximately 200 million tests each month for students and staff in the nation’s primary and secondary schools and nursing homes.”

But things could revolve. Testing efficiencies are improving and companies are working to develop faster and cheaper on-the-spot tests – if delivered widely enough — that could make a difference, the report says.

The team wrote, “By October 2020, at least 70 million trials will be conducted per month, based on the recently announced and expected market penetration.”

By January, the US may reach around 200 million trials monthly. More development is possible, experts said.

Trial of a major coronavirus vaccine halts

Meanwhile, AstraZeneca said that on Tuesday it has stopped testing of its Kovid-19 vaccine, one of three that are in the final stages of testing in the US, as one of the participants has unexplained illness.
The company said the affected volunteer is in Britain, but will be tested worldwide, but will be halted. AstraZeneca announced its Phase 3 trial debut in the US only last week.
AstraZeneca halts coronovirus vaccine testing after unexplained illness in volunteer

The stop may be temporary and the vaccine may not have caused the disease. The company is making sure before proceeding with more testing. The company did not provide details about the disease.

The company said in a statement, “This is a routine action that occurs in any test if there is a potentially unexplained disease while we are testing to maintain the integrity of the test.”

“In larger trials, the disease will be coincidental, but independently it should be reviewed to be carefully screened,” the company said.

Collins, NIH director, said the AstraZeneca grip is due to a “spinal problem”. Collins said the halt is “not unprecedented.”

Indeed, the Wellcome Trust absconded and Drs. According to Melanie Saville, Director of Vaccine Research and Development for Epidemiological Preparedness Innovations (CEPI), in the Vaccine Trial for Prevention of Vaccine Trial.

“In many ways, I think it shows that trial monitoring is working well,” Farrar said.

Two other Phase 3 vaccine trials

There are two other vaccine candidates in Phase 3 trials, one developed by Modern, the other by Pfizer and its German partner BioNotech. All three have US government funding and backing.

The Pfizer / BioNTech vaccine may prepare its candidate for regulatory approval by mid-October, said Ugur Sahin, CEO and co-founder of BioNTech, in an exclusive interview with CNN.
Trick-or-treating is banned in Los Angeles due to coronovirus exposure

“This is an excellent profile and I consider this vaccine … near perfect, and which has a complete profile,” Sahin said.

Pfizer and BioNotech say they have plans to deliver 100 million doses of their vaccine candidate BNT162 and 1.3 billion doses in 2021 by the end of the year.

Modern’s Phase 3 trial began on July 27, more than a month ago. The US government has signed a deal to give 100 million doses to the company after the vaccine was approved.

AstraZeneca’s pause on trial may have given the public more confidence that companies are upholding the first rule of safety, despite pushing from President Trump to get the vaccine more quickly.

Nine companies, including AstraZeneca, signed a pledge on Tuesday promising that they would not seek premature approval for a vaccine, and they would wait until they had the necessary data to show that They work safely.

CNN’s Eric Levenson, Allison Main, Lauren Mascarenhus and Amanda Watts contributed to this report.